迪哲医药完成定增事项 多家知名机构参与认购

Core Viewpoint - Dize Pharmaceutical successfully completed a private placement of A-shares, raising a total of 1.796 billion yuan, indicating strong market interest and recognition from institutional investors in the company's value and the innovative drug sector [2][3] Group 1: Fundraising Details - The private placement was priced at 43 yuan per share, which is 80% of the average price over the 20 trading days prior to the pricing date [2] - A total of 24 subscription entities participated, with 14 final allocation recipients, including well-known public funds and insurance capital [2] - Notable investors included Taikang Asset Management, Zhuque Fund Management, and UBS AG, highlighting the appeal of Dize Pharmaceutical to long-term capital [2] Group 2: Company Development and Products - The successful completion of the fundraising will accelerate the company's development and enhance shareholder value [3] - Dize Pharmaceutical is recognized as a representative of domestic innovative drugs, with two products, Shuwotai (舒沃替尼片) and Gaoruizhe (戈利昔替尼胶囊), already listed in China and included in the new national medical insurance catalog [3] - The company has submitted a marketing application for Shuwotai to the FDA, which has been accepted and prioritized for review, indicating potential for international expansion [3]